Abstract
The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.
| Original language | English (US) |
|---|---|
| Article number | 45681 |
| Journal | Scientific Reports |
| Volume | 7 |
| DOIs | |
| State | Published - Apr 4 2017 |
Fingerprint
ASJC Scopus subject areas
- General
Cite this
Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. / Qasaimeh, Mohammad; Wu, Yichao C.; Bose, Suman; Menachery, Anoop; Talluri, Srikanth; Gonzalez, Gabriel; Fulciniti, Mariateresa; Karp, Jeffrey M.; Prabhala, Rao H.; Karnik, Rohit.
In: Scientific Reports, Vol. 7, 45681, 04.04.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
AU - Qasaimeh, Mohammad
AU - Wu, Yichao C.
AU - Bose, Suman
AU - Menachery, Anoop
AU - Talluri, Srikanth
AU - Gonzalez, Gabriel
AU - Fulciniti, Mariateresa
AU - Karp, Jeffrey M.
AU - Prabhala, Rao H.
AU - Karnik, Rohit
PY - 2017/4/4
Y1 - 2017/4/4
N2 - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.
AB - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.
UR - http://www.scopus.com/inward/record.url?scp=85016930527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016930527&partnerID=8YFLogxK
U2 - 10.1038/srep45681
DO - 10.1038/srep45681
M3 - Article
VL - 7
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 45681
ER -